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3. Summary 
BACKGROUND: Alzheimer’s disease (AD) is an age-related progressive 
neurodegenerative disorder causing irreversible cognitive impairment. The prevalence of 
AD increases with age as does a number of other age-related physical illnesses. With an 
exception for a genetic impact and risk factors such as cardiovascular and 
cerebrovascular diseases no etiological factors have been identified. Usually, clinical 
trials on AD have recruited participants from memory clinics, hospitals or nursing homes 
using stringent inclusion criteria. These sampling methods could be at risk of selection 
bias. Current therapy for AD includes non-pharmacological and pharmacological 
symptomatic treatment. A number of studies on symptomatic treatment have reported 
contradictory results. Drug treatment of co-morbidities in AD could reinforce cognitive 
disabilities.  
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AIM OF THE STUDY: The main purpose of the present study was to examine the effects 
of stimulation therapy on cognitive test performance in community dwellers 65 years of 
age or older with a recent diagnosis of mild to moderate AD in Northern Norway. A 
secondary purpose was to examine whether donepezil increased the effect of stimulation 
therapy on cognition (Paper 3). During the study two additional purposes were included:  
1. To compare baseline characteristics between participants included by two different 
recruitment methods within the same geographical area (Paper 1) 
2. To compare co-morbidities, current medical treatment and inappropriate medication 
between participants with and without AD (Paper 2).   
DESIGN:  
1. A cross-sectional comparison of baseline characteristics between participants  
a. with AD included by two different recruitment methods (Paper 1) 
b. with and without AD regarding co-morbidities, current drug treatment and 
inappropriate medication (Paper 2)  
2. A two-by-two factorial interventional study comparing stimulation therapy and 
standard care to which a randomised, double-blinded, placebo-controlled trial with 
donepezil was added (Paper 3)     
PARTICIPANTS AND METHOD: The present study was population-based and 
conducted at a community level. One hundred and eighty-seven participants 65 years or 
older with a recent diagnosis of AD were recruited in nine rural municipalities; 100 by 
postal screening and 87 by general practitioners (GPs). In five municipalities the AD 
participants received structured stimulation therapy, and in the remaining four standard 
care. All participants were randomised in a double-blinded manner to donepezil or 
placebo. In addition 200 cognitively healthy participants 65 years or older were randomly 
selected by the screening program and included as control group. The clinical part of the 
study lasted from January 2006 until June 2009.  
RESULTS: AD participants recruited by screening were younger, more frequently men 
and had a higher Mini-Mental-State-Examination (MMSE) 1 sum score as compared to 
those recruited by GPs (Paper 1). In a cross-sectional comparison of co-morbidities and 
current medical treatments between AD participant and cognitively healthy controls, a 
significantly higher number of drugs were found in AD participants, despite no 
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significant differences in co-morbidities..Mean arterial blood pressure was significantly 
reduced and the mean number of antihypertensive drugs significantly increased among 
AD participants. The mean number of drugs and the frequency of inappropriate 
medication increased in AD nursing home residents (Paper 2).  
No time-point differences were found between AD participants receiving stimulation 
therapy and those receiving standard care. Both groups retained cognitive test 
performances during the one-year follow-up. Donepezil had no additional effect but 
significantly more adverse reactions (95% CI 1.5 to 8.7 p=0.002) as compared to placebo. 
A head-to-head comparison between stimulation therapy and donepezil did not reveal any 
time-trend differences in cognitive test performance (Paper 3).  
CONCLUSION: A community-based postal screening of cognitive function preceding 
clinical examination may be a suitable recruitment strategy in studies of early-stage AD. 
An increased number of drugs and inappropriate medication combined with reduced 
mean arterial blood pressure could deteriorate cognitive test performances in AD 
participants. AD participants retained cognitive test performance by receiving stimulation 
therapy during one year, but no better than those receiving standard care. Adding 
donepezil to these non-pharmacological treatment options did not improve outcome 
measures.  
ClinicalTrials.gov (Identifier: NCT00443014). EudraCT database (no; 2004-002613-
37). 
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The effect of stimulation therapy and donepezil on cognitive function in Alzheimer’s 
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5. Abbreviations  
AD   Alzheimer’s disease 
ADAS-Cog Alzheimer’s disease Assessment Scale, cognitive (Scale 0―70, 
increasing disability with increasing score) 
ADL   Activities of daily living 
BI Barthel Index (Scale 0―20, better function with increasing 
score) 
ChEI    Cholinesterase inhibitor 
CSF   Cerebrospinal fluid 
DSM-IV-TR   Statistical Manual of Mental Disorders fourth edition 
EOAD   Early-onset Alzheimer’s disease  
GCP   Good clinical practice 
GDS   Global Deterioration Scale  
GP    General Practitioner 
ICD-10  International classification of diseases 10
th
 Revision  
IQ-CODE   Informant Questionnaire―Cognitive Decline in the Elderly  
LOAD   Late onset Alzheimer’s disease 
MADRS Montgomery and Aasberg Depression Rating (Scale 0―60 
increasing depression by increasing number) 
MCI   Mild cognitive impairment 
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MMSE Mini-Mental State Examination (Scale 0―30, better function 
with increasing score) 
NPI  NeuroPsychiatric Inventory (Scale 0―144, increasing number 
of psychiatric symptoms by increasing number) 
NINCDS-ADRDA  National Institute of Neurological Disorders and Stroke-
Alzheimer Disease’s and Related Disorders  
OR Odds Ratio 
PET   Positron emission tomography 
RCT   Randomised clinical trial 
SCI   Subjective cognitive impairment 
VaD   Vascular dementia 
 
6. Introduction  
 
6.1 Casuistry 
In 1994, the Department of Psychiatry at the County Hospital in Bodø was invited to 
participate in a multicentre international Phase III clinical trial on AD. One of my 
patients with a recent diagnosis of AD was included in the study and allocated to active 
drug or placebo treatment in a double-blinded randomised manner. This patient was 
followed carefully every second week for four months. During this period, the patient’s 
cognitive function, quality of life and activity of daily living (ADL) improved, both 
subjectively and according to observations and formal testing. Patient and family were 
satisfied with the treatment. After four months the randomisation code was broken. My 
patient was a placebo users. I was astonished and the patient were disappointed. How 
could the cognitive and executive functions improve by placebo treatment?  
The question remained in my consciousness for years. Nine years later the first protocol 






7.  Background  
7.1 Definition of dementia 
Dementia is an acquired organic mental syndrome followed by general impairment of 
cognitive abilities such as memory, judgement and abstract thinking as well as 
personality changes. Dementia is irreversible and progressive and does not include 
functional mental disorders such as delirium or temporary impaired consciousness2.  
 
The present study focus on AD, a syndrome first described by the German psychiatrist 
Alois Alzheimer in 19063;4.  
 
7.2 Literature on the topic 
The main focus of the present study is the effect of stimulation therapy on cognitive test 
performance in an early-stage AD, to which donepezil treatment is added. Stimulation 
therapy comprises reality orientation, physical exercise, cognitive stimulation, 
reminiscence activities and various sophisticated sensory stimulations. Pharmacological 
treatment mainly involves cholinesterase inhibitors (ChEIs) and memantine.   
 
Scandinavian research centres have participated in interventional AD studies with ChEIs 
organised as multicentre RCTs 5-7. Only a few population-based screening programs 
aimed to recruit AD participants in clinical trials have been conducted8;9. A head-to-head 
comparison between stimulation therapy and ChEIs examining the effects on cognition in 
AD has been requested by the scientific community10 but has to my knowledge not been 
published.  
 
The literature listed below represents a brief review of the available knowledge of the 
effect of stimulation therapy and drug treatment on AD at the onset of the present study 11 
and a sample of recently published studies on the topic. A brief review of new evidence 
of the impact of placebos in clinical trials is added. A complete and updated reference list 





When the present study was initiated, three review papers of the effect of stimulation 
therapy on AD were identified in PubMed.  
1. In 2004 Heyn et al. published a meta-analysis of the effect of exercise training on 
elderly individuals with cognitive impairment and dementia. Published articles 
and non-published manuscripts from 1970 to 2003 were identified and 30 studies 
(2020 participants) were included. Heyn et al concluded that “physical training 
increased fitness, physical function, cognitive function, and positive behaviour in 
people with dementia and related disorders”12. 
2. In 2003 a review by Clare et al evaluated the impact of cognitive training and 
cognitive rehabilitation on early-stage AD. Records from MEDLINE, EMBASE, 
CINAHL, PsycINFO and many other databases, waere searched in April 2003. 
Six studies comprising cognitive training with a RCT design were included. Clare 
et al concluded that the results did not provide strong support for the use of 
cognitive training for early-stage AD or VaD. However, only a few studies were 
available, hampered with methodological limitations. No conclusion could be 
drawn about cognitive rehabilitation due to a complete absence of RCTs on the 
topic13. 
3. In 2003 Luijpen et al published a review of studies examining the effects of non-
pharmacological stimulation on cognition, affective behaviour and the 
sleep―wake rhythm of cognitively impaired and demented elderly. The 
stimulation therapy comprised bright light, physical activity and tactile 
stimulation. Luijpen et al concluded that all three types of stimulation appeared to 
increase cognitive function14. 
 
Several clinical trials examining the effect of stimulation therapy on AD have been 
reported during the last 15 years15-19. In some of them stimulation therapy was added 
to ChEI treatment20-22. The most important recent trials and review papers on the 
topic are listed below.   
1. In 2003 Spector et al published a well-designed single-blinded randomised 
multi-centre controlled trial with stimulation therapy for people with 
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dementia. The study included 201 individuals with dementia. The main 
outcome measures were changes in cognitive function and quality of life as 
measured by MMSE, ADAS-Cog and the Quality of life – AD scale. The 
authors reported significant improvement in cognition and quality of life in 
the intervention group23. 
2. In 2006 Graff et al published a single-blinded randomised controlled trial to 
assess the effectiveness of community-based occupational therapy for the 
ADL functions of patients with dementia and the sense of competence of their 
caregivers. The study included 135 participants with mild to moderate 
dementia. Ten sessions with occupational therapy during 5 weeks were 
provided, and the results were evaluated after 6 weeks and after 3 months. The 
authors concluded that occupational therapy improved activities of daily 
living of the patients and reduced the burden of the caregiver16.  
3. In 2010 Olazaran et al published a systematic review and meta-analysis of the 
entire field of evidence-based knowledge of non-pharmacological therapy to 
treat AD. They concluded that non-pharmacological therapy was a useful and 
cost-effective approach to improve outcomes in AD and related disorders.24 
4. Yamaguchi et al (review 2010) focused on how therapists should 
communicate with patients and caregivers and offered some proposals for 
non-pharmacological intervention in suitable supportive psychosocial context 
to obtain optimal results25.  
5. In two recent review papers on stimulation therapy in AD, Ballard et al. 
(March 2011) and Andrade et al. (March 2009) both emphasise the positive 
impact of cognitive training, occupational activities and physical exercise on 
cognition and activities of daily living in patients with early-stage AD26;27 
 
ChEI treatment 
Early loss of basal forebrain cholinergic neurotransmission is a biochemical hallmark of 
AD28;29. Since the early 1990s several drugs with cholinesterase-inhibiting effects have 
been developed and tested in clinical trials, including symptomatic treatment of mild to 
moderate AD. However, the clinical effects, relevance and the cost-effectiveness of these 
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drugs have been questioned. The literature listed below reflects some of the scientific 
uncertainty related to the effect of ChEI treatment of AD at the time when this study 
began, in addition to recently published papers on the topic. A number of review papers 
on ChEIs have been identified and all of them concluded that ChEIs have a small to 
modest beneficial effect on cognition. One of the review papers included clinical 
recommendations30-36.  Four of the review papers are summarised below.  
1. Trinh et al reviewed papers with ChEI-treated AD participants from 1966 to 
December 2001. Twenty-nine parallel groups or crossover double-blinded RCTs 
of outpatients treated for at least four weeks were included. They concluded that 
ChEIs had modest beneficial effects on neuropsychiatric and functional outcomes 
for patients with AD.  No conclusion could be drawn as to institutionalisation or 
quality of life33. 
2. A Cochrane review by Birk et al 2002 included 16 trials of 12, 24 or 52 weeks 
involving 4365 participants treated with donepezil 5 mg or 10 mg. A statistically 
significant effect on cognition measured by ADAS-Cog was reported after 52 
weeks of treatment. Some improvement was found in global clinical state as rated 
by an independent clinician. Benefits of treatment were also seen in measures of 
activities of daily living and behaviour. Significantly more adverse reactions were 
found in participants on 10 mg donepezil compared to placebo30. 
3. Raina et al.(2008) conducted a review of 59 unique studies from 1986 through 
2006 that evaluated the effectiveness of ChEI and memantine in achieving 
clinically relevant improvements, primarily in cognition, global function, 
behaviour and quality of life, in patients with dementia. Both ChEI and 
memantine had consistent but small effects in the domains of cognition and global 
assessment (the clinical-based impression of changes with caregiver input). Fewer 
consistencies were found for behaviour and quality of life. Most studies had short 
duration. The authors concluded that “treatment of dementia with ChEI or 
memantine can result in statistically significant but clinically marginal 
improvement of cognition or global assessment”32. 
4. A clinical practice guideline for current treatment of AD in the US was published 
by Qaseem et al. in March 2008. The guideline recommended that clinicians base 
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the decision to initiate a trial of therapy with ChEI or memantine on 
individualised assessment taking tolerability, adverse effect profile, ease of use 
and medical cost into consideration31.  
 
One of the classic trials examining donepezil for AD treatment was published by Rogers 
et al. in 199837. They highlighted cognitive deterioration as an inherent trajectory of AD 
and showed that cognitive performance could be maintained by nearly one year of 
donepezil treatment. However, this randomised, placebo-controlled and blinded part of 
trial was run for only three months. At that time the study was opened and the AD 
participants in both groups were treated only with donepezil without a control group. 
However, the reference to the inherent AD trajectory as the background for evaluating the 
effects of symptomatic treatment with donepezil makes this study one of the most 
important on the topic. Stabilising cognitive performance has for a long time been 
identified as an important treatment outcome in AD research38. 
 
Due to ethical considerations few placebo-controlled trials with ChEIs for AD treatment 
have been conducted during the last 10 years 
 
Several RCTs with disease-modifying drugs, including the phenserine enantiomer (a 
derivate of physostigmine) have been published7. The results for phenserine enantiomer 
were not clinically significant as measured by ADAS-cog, the clinician’s impression of 
change and the caregivers´ input29. The results of other RCTs of disease-modifying drugs 
for AD have so far been disappointing29. 
 
Placebo 
A placebo was originally defined as a dummy medical treatment but has recently been 
described as any dummy treatment administered to the control group in a controlled 
clinical trial2. The placebo effect is defined as the favourable impact of placebo (with a 
biologically inert substance or shame intervention) on the course of a disease state. The 
placebo effect is reinforced by classical Pavlovian conditioning, firm diagnosis, clinical 
testing, novel therapeutic procedures, verbal suggestion of a beneficial outcome and a 
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positive doctor-patient relationship39-41. The placebo effect in clinical trials has gained 
more attention in recent years. Several studies have described the placebo effect as a 
complex interaction between the psychosocial context of the intervention and the 
expectation of a clinical benefit42;43. In brain-activating rehabilitation the treatment is 
recommended to be implemented in a favourable psychosocial context utilising the 
impact of expectation and verbal suggestion25. The impact of the placebo effect in clinical 
trials has probably been underestimated43. In a recent review Fournier et al (2011) found 
that a true effect of antidepressant drugs was nonexistent or negligible compared to 
placebo amongst depressed patients with mild, moderate and even severe baseline 
symptoms, whereas the true antidepressant drug effect was large for patients with very 
severe depressive symptoms 44. The first evidence of a biochemical mechanism 
underlying the placebo effect, was demonstrated by Levine et al. in 1978. They found 
that the placebo analgesia effect could be blocked by naloxone. This observation 
suggested that a placebo could induce the release of endogenous opioids. In recent years 
several studies using functional magnetic resonance imaging techniques have visualised 
the role of placebos in releasing endogenous neurotransmitters in the brain40;43;45 
 
Few studies have focused on the placebo effect in AD. Benedetti et al. have postulated 
that the placebo mechanism depends upon preserved frontal lobe function. They 
evaluated lidocaine pain relief in AD individuals compared to controls. The placebo 
effect in AD participants with mild cognitive impairment (MMSE 24 ± 1.22) was 
preserved but it was significantly reduced in patients with moderate to severe AD 
(MMSE 15.6 ± 1.9) compared to controls. A reduced placebo effect was found to be 
correlated to reduced frontal executive function as measured by the Frontal Assessment 
Battery 40;46. 
 
7.3 Aging and cognition 
Memory complaints amongst the elderly are usually interpreted as a clinically normal 
age-related condition. However, approximately half of elderly subjects have no cognitive 
complaints and objectively normal neuropsychiatric performance. The prevalence of age-
related self-reported cognitive disturbances constituted 20% in one study and varied 
 15 
between 25% and 56%  in three other studies of individuals 65 years of age or older47;48. 
Cognitive complains in the elderly are also associated with co-morbidities such as 
depression and pain48;49.  
 
Age-related memory impairment and mild cognitive impairment (MCI) 
MCI50 is supposed to be a continuum or an intermediary stage of cognitive disability 
between age-related memory impairment and early dementia stages, and it could be 
reversible51. The most commonly used criteria define MCI as a condition of subjective 
memory complaints, abnormal memory for age, normal executive functions and no 
dementia52-54. Cognitive impairment should be present without any interaction with ADL. 
Depending on the diagnostic tools and criteria55, the incidence rate of MCI individuals ≥ 
65 years of age progressing to dementia range from 1 to 25% in one review paper56, from 
10 to 15% in another57 and was 5.4% in one single cohort study58. In the cognitively 
healthy population ≥ 65 years, the incidence rate of dementia is 2%57-59. Amnestic MCI is 
a pre-clinical phase of AD lasting several years before the diagnostic criteria of AD are 
fulfilled48;60. According to Reisberg et al. (2008) individuals with subjective cognitive 
impairment (SCI) and normal MMSE are at a significantly higher risk of cognitive 
decline compared to individuals with no subjective cognitive impairment (NCI) and 
normal cognition. During a mean follow-up of seven year, 54.2% (n=90) of the SCI 
group revealed cognitive deterioration compared to 14.9% (n=7) of the NCI group 
(p<0.001)61. In the SCI group 71 of 90 individuals declined to MCI and 19 to dementia.  
 
7.4 Alzheimer’s disease 
AD represents 65―70% of all dementia diagnoses, 90% of which occurs in individuals 
who are 65 years of age or older. The cardinal initial symptom of AD is impaired 
episodic memory and an inability to retain recently acquired information. With disease 
progression impairment of other cognitive domains, such as visuospatial, verbal and 
executive functions and semantic memory, occurs. Changes of social behaviour and 
personality are common, especially in advanced disease stage62. Increasing cognitive 
disability gradually influence ADL63. Delusions and psychotic behaviour are not typically 
initial symptoms but can occur at any time during the disease course62.  The natural 
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cognitive deterioration is characterised by a yearly 2 – 3-point decrease in MMSE  sum 
score corresponding to an increase of 6 – 12 points in Alzheimer’s disease Assessment 
Scale, cognitive (ADAS-Cog)64 score65-67. 
 
7.5 Epidemiology of AD 
The incidence and prevalence of AD increase steeply with ageing and depend strongly on 
the diagnostic criteria68-70. The overall prevalence ranges from 5.4 to 10.3% in a 
population ≥ 65 years3;71. The prevalence of AD is 3% in the 65―74 year age group and 
increases to 47% in those above 85 years. No significant differences amongst countries 
have been reported72-74, although differences amongst ethnical groups are found75;76. 
Increased longevity and a steadily increasing number of individuals reaching the age of 
retirement in developed countries in the years to come will reinforce the impact of AD on 
public health services and may represent an unsustainable economic burden on 
societies3;72;73;77-81.  
   
AD is a heterogeneous syndrome. Both genetic and environmental factors have an 
etiological impact82. The genetically attributable risk of AD is postulated to be 70%27. 
Early-onset AD (EOAD) (<65 years of age) accounts for less than 10% of all AD 
individuls83 84. Late-onset AD (LOAD) is a sporadic condition with an inherent but not 
genetically dominant disposition85;86. Individuals who are homozygous for the APOE ε4 
allele are at an increased risk of LOAD85 and having a close relative with AD increases 
the risk of AD. Known environmental risk factors include negative lifestyle habits (i.e. 
excess weight, inactivity, smoking) and co-morbidities such as metabolic syndrome, 
hypertension in midlife and cardiovascular and cerebrovascular diseases87;88 
 
Level of education may modify the deterioration of AD89;90, providing support to the 
“cognitive reserve” model65. A meta-analysis in 2006 confirmed that low education may 
be a risk factor for dementia91. 
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Insufficient nutrition, especially reduced consumption of vitamin B12 and folic acid, has 
been associated with AD, but convincing causal interaction is still lacking92, and the 
deficiency stages can be secondary. 
 
7.6 The histopathological findings in AD   
The AD brain shows medial temporal lobe atrophy especially in the entorhinal cortex and 
hippocampus (in the floor of the inferior horn of the lateral ventricle) and in parts of the 
frontal and parietal lobes93. The histopathological hallmarks of AD are senile plaques and 
neurofibrillary tangles in the cortex27. 
 
7.7 Diagnosing AD 
The diagnosis of AD in general practice is based on a careful medical history usually 
extended by a caregiver; cognitive and neuropsychiatric tests; clinical examination and 
neuroimaging. In memory clinics, more advanced diagnostic tools and procedures are 
provided. Typical findings are problems in episodic memory, visuospatial tasks, verbal 
and executive functions. The diagnosis is supported with hippocampal atrophy in 
magnetic resonance imaging (MRI), changes in biomarkers in cerebrospinal fluid (CSF) 
such as elevated total tau and phosphorylated tau protein, low level of β-amyloid42 in 
cerebrospinal fluid (CSF)94, temporoparietal hypoperfusion in Single Photon Emission 
Computer Tomography (SPECT), decreased glucose metabolism in tempo-parietal lobes 
and increased amyloid deposits in frontal lobes as assessed with positron emission 
tomography (PET)95. 
 
7.8 Screening of cognitive impairment and other functions in AD 
MMSE is the test most widely used to screen and monitor changes in cognitive function. 
The cognitive domains assessed are memory, language, abstraction, visouspatial and 
executive functions. The test favours individuals with higher education96. In Norway the 
clock drawing test97 is also used routinely to assess executive and visuospatial functions. 
It is validated and easy to use. 
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In AD drug trials, ADAS-Cog is the most widely applied cognitive test to follow disease 
progression98. ADAS-Cog covers the typically deteriorated cognitive domains in AD, and 
frequent repetitions do not tend to improve the results. It is validated and translated into 
Norwegian.  
 
A number of additional cognitive, neuropsychiatric, ADL and depression tests and semi-
structured questionnaires have been developed.  
 
Various population-based screening tools of cognitive impairment and AD have been 
evaluated. Caregiver-based telephone interviews have good agreement with the 
assessment by general practitioners8. A two-step population-based screening of cognitive 
impairment by a postal questionnaire and a subsequent telephone interview was 
developed by van Uffelen et al. Individuals with probable MCI as diagnosed by screening 
were invited to a face-to-face clinical assessment. Screening compared to clinical 
assessment had a 41% agreement in diagnosing MCI 99. In general, self-administered 
postal questionnaires have several advantages over face-to-face assessment. They are 
cheap and suitable in surveys, requiring no training and provide a high response rate in 
elderly people. In England and Wales a postal screening approach for morbidity in the 
elderly has been advocated100. 
 
7.9 Diagnostic criteria 
Three sets of diagnostic criteria based on clinical examination are most frequently used in 
clinical trials. Two of them have been developed and revised over years (ICD-9 → ICD-




According to ICD-10101;102 dementia in LOAD is a chronic neurologic disorder involving 
several cognitive domains in individuals ≥ 65 years. A LOAD diagnosis presupposes 
impaired memory (especially short-term and episodic memory) and disturbances in one 
or more executive functions such as abstracting, judgment and problem solving. 
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Disturbances in language (especially semantic memory) and visuospatial functions 
strengthen the diagnosis. The observed cognitive deficits should interfere with social or 
occupational activities and represent a significant decline from a previous level of 
functioning. Decline in cognitive function should be steady and progressive and not due 
to delirium, depression, endocrine disorders, nutrition deficiencies, infectious diseases or 
other dysfunctions in the central nervous system. Decline in cognitive function should 
have lasted for at least six months and consciousness disturbances should be excluded69.  
 
DSM-IV TR 
According to the Statistical manual of mental disorders, fourth addition (DSM-IV-TR)103, 
a dementia diagnosis of AD requires both memory deficits (especially impaired ability to 
learn new information and recall previously learned information) and deficits in at least 
one additional cognitive domain (aphasia, apraxia, agnosia, and/or executive functions), 
both interfering with social functioning and ADL94. The course is characterised by 
gradual onset and continuing cognitive decline. Delirium, depression and other causes of 
dementia or cognitive impairment should be excluded. Normal consciousness is required.   
 
NINCDS-ADRDA 
 The National Institute of Neurological Disorders and Stroke-Alzheimer Disease and 
Related Disorders (NINCDS-ADRDA)103 criteria for probable AD require a clinically 
and neuropsychologically established diagnosis of dementia including deficits in at least 
two cognitive domains: 1. Memory impairment; i. e. the loss of learning ability and/or the 
ability to recall previously learned information. 2. One or more of the following 
disturbances: apraxia, aphasia, agnosia and executive functions. Loss of function should 
be a substantial decline from previous abilities and should influence ADL. The 
disturbances should begin slowly and gradually become more severe. Delirium should be 
excluded. The criteria include normal motor, sensory, and coordination functions at an 
early disease stage and the absence of focal neurologic symptoms. Laboratory tests and 
cerebral computed tomography (CT) should exclude other possible causes of cognitive 
impairment before the diagnosis of Alzheimer's disease can be made with confidence. 
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These criteria also include neuropsychological tests to provide confirmatory evidence of 
the diagnosis. 
 
Although no gold standard diagnostic criteria of AD exist, Ballard et al. emphasise that 
the diagnostic criteria and procedures mentioned above have a sensitivity and specificity 
> 80 % for discriminating Alzheimer’s disease and healthy cognition27. Dubois et al 
emphasise that DSM-IV-TR and NINCDS–ADRDA criteria have been validated against 
neuropathological findings with diagnostic accuracy ranging from 65 to 96%. In a recent 
study from Lund, Sweden, 84% of  patients with a clinical AD diagnosis had a significant 
Alzheimer neuropathological component104. The specificity of the present diagnostic 
criteria against other dementias is only 23–88%94. New diagnostic options such as CSF 
biomarkers and functional PET have increased accuracy and are currently closest to a 
gold standard diagnostic tool94. However, the sensitivity and specificity of the current 
routinely available diagnostic tools, relying on cognitive tests and medical history, are 
still insufficient. In combination with various diagnostic criteria, this insufficiency could 
influence the calculation of both prevalence and incidence rate69;70 and makes the 
calculation of predictive values and the accuracy of current tests less certain.  
 
7.10 Therapeutic options  
As long as no causal treatment of AD exists, therapies must concentrate on prevention 
and symptomatic treatment105-107 by means of stimulation with and without 
pharmacological treatment or pharmacological treatment alone. The development of 
efficient disease-modifying drugs has until recently failed27.  The unsuccessful approach 
focused on a causal therapy has demonstrated a probably insufficient basic understanding 
of AD pathogenesis29. AD is a multifactor disorder108. A single drug acting against a 
single target linked to a single pathogenic pathway or disease is not likely to be found29. 
At the moment, intervention against risk factors and symptomatic treatment is the only 





Intervention on risk factors in AD 
With the growing prevalence of AD, sustainable intervention methods against known risk 
factors are important. Health conditions and lifestyle are risk factors associated with AD 
and could be the most reasonable targets of an optimal preventive strategy87;88. Lifestyle 
habits including nutrition and physical activities may modify many risk factors109. 
Increasing evidence suggests that an active lifestyle among the elderly including social, 
mental, and physical engagement may prevent AD. The strongest evidence is found for 
increasing an individual's level of physical activity, followed by the cessation of smoking 
110;111.  
 
Treating hypertension in midlife may reduce the risk of dementia112. Interventions and 
medical treatment of cardiovascular risk factors in AD are supposed to delay AD 
progression and improve prognosis. So far treating cardiovascular risk factors and 
metabolic syndrome have not influenced cognitive decline or AD progression113. There is 
conflicting evidence about the preventive effect of antihypertensive treatment27;113. 
However, physical activities and interventions to promote a healthy lifestyle will 
probably reduce the incidence of several AD risk factors27 and are the most promising 
AD-modifying efforts114.  
 
Symptomatic treatment (non-pharmacological and pharmacological therapy) 
As AD is a progressive neurodegenerative disease, any considerable improvement of 
cognition is not likely. The best obtainable result of symptomatic treatment would be 
postponing an inevitable cognitive deterioration. This is an esteemed goal for 
symptomatic treatment, and verified by a number of clinical trials on the topic37;115;115;116. 
How sustainable this postponement of cognitive decline could be is still unknown, but 




Various non-pharmacological interventions for individuals with dementia are available, 
including physical exercise, occupational therapy, cognitive rehabilitation and social 
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stimulation.12;13. A number of small interventional studies have been conducted in recent 
years and most of them report positive effects of stimulation therapy compared to control 
treatment10;15;23;117;118. A meta-analysis from 2004 on exercise training in elderly with 
dementia reported improved fitness, physical and cognitive function, and positive 
behaviour12.  A new systematic review performed by Olazaran et al. (2010)24 examined 
179 RCTs on stimulation therapy. According to the criteria of Oxford University’s Centre 
for Evidence-Based Medicine, 13 high-quality trials were found of which seven (54%) 
reported positive results; 113 of 166 (68%) low-quality trials were positive. In spite of 
these results, Olazaran et al. concluded in this way: “Non-pharmacological treatment 
emerges as a useful, versatile and potentially cost-effective approach to improve 
outcomes and quality of life in AD and related disorders for both persons with dementia 
and caregivers”. A third systematic review (2008) dealing with mild to moderate AD, 
provided practical recommendations on non-pharmacological and pharmacological 
interventions. One conclusion was that there is good evidence that individualised exercise 
programs have an impact on functional performance119. Furthermore, Lujipen et al 
concluded in a review that improvement in cognition and affective behaviour by bright 
light, physical activity and tactile stimulation and by cholinesterase inhibitors had similar 
effect sizes. All three types of stimulation appeared to increase cognitive function14.  
 
Drug treatment (ChEI and memantine) 
During the last 15 years, the AD neuropathological focus has been on insufficient 
neurotransmission in affected brain areas, initially on cholinergic and glutamate synapses 
in particular. Since the early 1990s several drugs with ChEI effects have been developed 
and tested. The external validity of these early phase III RCTs on ChEI was hampered by 
short duration and by the restrictive subject selection criteria120 which would have 
excluded 90% of eligible community-dwelling AD individuals121. One large community-
based industry-independent donepezil study included 595 AD individuals and lasted for 
more than one year (the AD2000 trial)122. An increase in mean MMSE sum score of 0.8 
points in the donepezil group over placebo was found (p<0.001) whereas other outcomes 
were insignificant32. The main conclusion from meta-analyses of cholinesterase inhibitors 
is that ChEIs (donepezil, rivastigmine and galantamine) have a modest beneficial effect 
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on cognition and a questionable clinical efficacy30;36;123;124. In Norway, three 
cholinesterase inhibitors have received legal marketing for symptomatic treatment of 
mild to moderate AD. A guideline for dementia treatment in general practice 
recommends that clinicians should base their decision to prescribe ChEI or memantine on 
individualised assessment, taking tolerability, adverse effect profile, ease of use and 
medical cost into consideration31.  
 
Therapy combining non-pharmacological and pharmacological treatment 
The effect of stimulation therapy in patients treated with ChEIs has been evaluated in 
several studies19;20;22;125. In these studies, AD individuals were randomised to stimulation 
therapy combined with ChEI or ChEI only (controls). These studies were open or single-
blinded and reported significant effects of stimulation therapy added to ChEI. No studies 
have so far compared ChEI with stimulation therapy in a head-to-head clinical trial10. 
 
7.11 Clinical trials, recruitment methods and external validity  
Most clinical trials on AD using stringent inclusion criteria have recruited participants 
from memory clinics, hospitals or nursing homes126.  In contrast, some trials have 
recruited AD participants by advertising in newspapers. These methods provide samples 
with different characteristics. Hence, the validity of these studies is questionable and the 
results from some of these studies could hardly be generalised127.  
 
7.12 Co-morbidities and drug treatments in AD individuals 
As a consequence of the increased number and severity of co-morbidities in AD 
individuals128-130 necessary medical treatment could be more extensive compared to 
cognitively healthy individuals. Neuropsychiatric symptoms in AD are common, 
especially in advanced disease stages. The symptoms could require treatment with 
psychotropic drugs. Increasing the number of drugs administered, especially psychotropic 





Co-morbidity and Alzheimer’s disease 
AD is associated with metabolic syndrome133, hypertension in midlife134 and increased 
cardio- and cerebrovascular disease burden88. Ischemic disease affects 60% to 90% of 
AD individuals, with major cerebral infarctions representing one-third of vascular lesions 
in autopsy cases108. Arteriosclerosis and reduced cerebral perfusion reinforce cognitive 
impairment in AD individuals in an additive or synergistic manner82;135-138. The Cache 
study has reported a more rapid AD progression in patients with atrial fibrillation, 
hypertension or coronary heart disease139. Deschaintre et al. have reported similar 
results140. The number of co-morbid medical illnesses in AD increases with disease 
severity128;141. In addition, AD individuals have more serious medical co-morbidities than 
comparable persons without cognitive impairment129. Dementia in elderly people is 
associated with low blood pressure142, but this could be a confounder, as low blood 
pressure by itself may predict death143. Pneumonia, febrile episodes, and eating problems 
are frequent complications in patients with advanced dementia, and these complications 
are associated with high 6-month mortality rates144.  
 
Inappropriate drugs 
Inappropriate medical treatment in the elderly has been an increasing concern in geriatric 
practice for years. Few studies have specifically addressed inappropriate treatment in 
AD145;146. Increasing the number of drugs increases the risk of adverse reactions and 
inappropriate medication131;146-148. Efforts have been made to define suitable guidelines 
and treatment criteria in the elderly. Beers´ criteria for inappropriate drugs were the first 
guidelines in the field. The criteria defined inappropriate medications in geriatric practice 
according to drugs licensed in the USA149 but did not address drug interactions or 
inappropriateness with or without specific diagnoses150;151. Rognstad et al. have through a 
Delphi process compiled a list of 36 explicit criteria for drugs clinically relevant for 
general practice in Norway, and considered potentially inappropriateness for elderly 
people (≥ 70 years). This list does not address specific diagnoses either151. The STOPP 
criteria define inappropriate drugs according to drug interactions and common geriatric 
disorders152 However, Barnett et al. question the validity of the full list of potentially 
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inappropriate drugs in older people because no significant impact on mortality has been 
found153;154 
 
More serious medical co-morbidities in AD individual may call for more extensive 
medical treatment compared to cognitively healthy persons. As a result, AD individuals 
have an increased risk of adverse drug reactions and inappropriate drug treatment147;148 
 
8. Purpose of the study 
The main aim of this study was to examine the impact of stimulation therapy on cognitive 
performance in individuals ≥ 65 years old with a recent diagnosis of mild or moderate 
AD.  
 
A secondary aim was to examine whether donepezil had an additional effect on cognitive 
performance when combined with stimulation therapy.  
 
During the progression of the trial, two additional study aims were adopted to compare:  
1. baseline characteristics in AD individuals recruited by two different methods from the 
same population  
2. the prevalence of co-morbidity and drug burden between AD individuals and 
cognitively healthy controls.  
 
9. Methods 
9.1 Participants and recruitment methods 
In clinical practice 
Two hundred participants with a recent diagnosis of AD were expected to be examined 
and included in the study by general practitioners in nine rural municipalities in Northern 
Norway between January 2006 and December 2007. However, during 2006 only 27 AD 
participants were included in the study. By then it was obvious that a presupposed sample 




The participating municipalities were selected from municipalities employing competent 
and professional health providers in rural Northern Norway. The general practitioners 
were well prepared for scientific studies and engaged in evidence-based medicine. 
However, as it came to examining and diagnosing dementia, only 14 of 70 GPs in the 
participating municipalities diagnosed and recruited AD patients to the study. This is in 
line with experiences from other studies155;156. GPs hesitate to diagnose mild cognitive 
impairment or early-stage dementia and cognitive impairment is disregarded both by 
relatives and health professionals, although this stage of cognitive impairment gives the 
most promising interventional opportunity8;157;158.  
 
Population-based screening 
As a consequence of the low inclusion rate by GPs during the first year, the recruitment 
method was extended in June 2007 to include a population-based screening of cognitive 
impairment by mail. An invitation letter enclosing a questionnaire modified from the 
Cambridge Examination for Mental Disorders of the Elderly159 and Strawbridge et al160 
was sent to all inhabitants ≥ 65 years old in the participating municipalities. The 
questionnaire comprised six questions concentrating on the main cognitive domains 
affected in AD (see Postal Questionnaire). To my knowledge this was the first 
community-based screening of cognitive impairment in Scandinavia and one of the first 
screening procedures by mail presented in the literature47;155. 
 
Postal Questionnaire 
1. Do you want to participate in the Dementia study?  
2. Has your memory deteriorated? 
3. Do you forget where objects were left? 
4. Do you have difficulties finding the appropriate words? 
5. Do you have difficulties in managing daily activities, which earlier represented no 
problem? 
6. Have you been examined for memory impairment before? 
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An algorithm was defined, and individuals answering in accordance with it were invited 
to undergo cognitive tests and clinical examination (see Algorithm). To reach a sufficient 
sample size the recruitment period was extended to March 2008. 
 
Algorithm  
Individuals invited to undergo cognitive tests and clinical examination answered 
1. “Yes” on question 1, 2, 3, 4, and 5. “No” on question 6 
2. “Yes” on question 1, 2, 5 and 3 or 4. “No” on question 6 
 
At the end of the recruitment period, 187 participants were included in the study; 87 were 
recruited by GPs and 100 were recruited by population based screening (Flowchart 1). 
Because two different recruitment methods were used in the study, it was important to 
determine whether baseline characteristics differed across recruitment methods and 
whether the two samples were equally distributed in the municipality groups. Other 
studies have shown that different recruitment methods could have a significant impact on 
study results and reduce validity. The first paper from the study compares baseline 
characteristics between the two samples47. The study period was 39 months, 27 of which 
were devoted to recruitment. 
 
Cognitively healthy controls  
Seven hundred ninety-one individuals answered “Yes” to the question on participation 
and “No” to the rest. From this group, 500 individuals were randomly selected by the 
Clinical Research Centre at the University Hospital in Northern Norway and invited to a 
clinical examination, including cognitive testing, aiming to act as a control group for the 
AD participants. Two hundred individuals were confirmed cognitively healthy, and then 
included in the study (Flowchart 1). The third paper from this study presents the main 
results of the interventional program whereas the second paper compares co-morbidities 





























9.2 Two-by-two factorial design 
As a consequence of the diversity of design, study duration and number of stimulation 
sessions in prior studies of stimulation therapy, we aimed to design a study being able to 
cope with these methodological challenges. The study had an open branch consisting of 
AD participants receiving stimulation therapy or standard care. All AD participants were 
double-blinded randomised to donepezil or placebo in a two-by-two factorial fashion. 
This design enabled a number of cross-analyses between subgroups including a head-to-
Population-based 
screening by mail 
n=11807 




AD individuals included after 
screening and examination 
n=100 
Answered NO to all questions 
concerning cognitive impairment and 
YES to the question of participation 
n=791 
Randomisation 
Invited to participate in 
the control group 
n=500 
Confirmed cognitively 
healthy and included 
in the control group 
n=200 
AD individuals 
included by GPs 
n=87 
AD individuals 
included in the study 
n=187 
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head comparison between donepezil and stimulation therapy (Flowchart 2). To our 
knowledge, no study with the same design has been published in the field of AD 
research. 
 
Flowchart 2  
 
9.3 Outcomes 
MMSE sum score was defined as the primary outcome. The results of ADAS-Cog and 
Clock drawing test were defined as secondary outcomes. Basic activities of daily living 
were assessed with the Barthel Index (BI)161, the Neuropsychiatric Inventory (NPI)162 
was used to identify psychiatric symptoms whereas depression was assessed with a semi-
structured questionnaire and with the Montgomery and Aasberg Depression Rating Scale 
(MADRS)163. 
 
9.4 Organisation and management of the study 
The study was administered from a rural municipality, Steigen, in the county of 




Interventional municipality group 
Standard care 
Control municipality group 
 
The donepezil group 
included; 
Donepezil + Stimulation  
Donepezil + Standard care 
The placebo group included; 
 
Placebo + Stimulation  
Placebo + Standard care  
Randomisation Randomisation 
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northernmost and the southernmost points of the participating municipalities. The 
distance between these extreme points was 800 km (Map 1). 
 
 
Map 1 showing the participating municipalities 
 
     Lenvik in Troms (c) 
     Sortland (i) 
      Ballangen (i)  
          
        Vestvågøy (i)  
 
 
         Steigen (i) 
         Fauske (i) 
    
        Vefsn (c) 
       
        Brønnøy (c) 
 
        Sømna (c) 
 
 
c= control municipality 






The staff of the Dementia Study in Northern Norway in front of the research vehicle. From the left hand 
side: Herdis Svendsen, Fred Andersen, Merethe Hjertø and Kristin Tverback 
 
The staff consisted of two test technicians, one research nurse and the project leader. 
They were all employed at the municipality of Steigen, which also offered office facilities 
for the study. The test technicians performed all tests in the study, among AD participants 
and in cognitively healthy controls. In addition, they acted as monitors of the 
interventional program. The monitoring procedures were approved by the Norwegian 
Medicine Agency. As the AD participants were diagnosed and included consecutively 
and followed up every fourth month for one year, the test technicians had to visit the 
participating municipalities regularly during a total study period of three years. The 
research nurse conducted the daily administration of the study and scheduled travel for 
the test technicians. She also made appointments with the participants and their care-
givers. All participants were examined, tested and monitored at the municipality level, 
sometimes in their own homes. All data were collected while the participants were 
 32 
situated in their own district, and the data were recorded consecutively by the staff at the 
study centre. The project leader surveyed and supervised the daily administration.  
 
All participants recruited by screening with and without cognitive impairment were 
examined and diagnosed in their own district by the project leader and physicians from 
the Geriatric Department at the University Hospital in Northern Norway.  
The scientific advisory board at The University of Tromsø, the County Hospital of Bodø 
and the Geriatric Department at Karolinska Institutet in Stockholm supervised the study 
regularly.  
 
9.5 Validating study groups  
The study was community-based and run on a municipality level. Nine rural 
municipalities in Northern Norway with 70000 inhabitants were engaged. The population 
in the age group ≥ 65 years was 11807. The participants in five of the municipalities 
received stimulation therapy whereas the participants in the remaining four received 
standard care (the control municipality group) (Flowchart 1 and 2).  
 
The municipalities were selected for the study and allocated to offer stimulation therapy 
or standard care according to some basic criteria including number of inhabitants, age 
distribution and ethnic homogeneity. A high professional competence level was required, 
and the primary health facilities needed to be organised and developed in accordance 
with the principles of good clinical practice and national guidelines. Choosing a 
maximum distance and pursuing the least contact between municipalities offering 
stimulation therapy or standard care were done to minimise the risk of dilution. These 
selection criteria were difficult to comply with at random.  
 
All participants were allocated to donepezil or placebo in a randomised manner, in blocks 
of four to six by the Clinical Research Centre at the University Hospital in Northern 
Norway. No significant differences in baseline characteristics were found between 




The deficit in professional competence was reflected in an unsustainable organisation of 
dementia care in general and a lack of any option for individual therapeutic adjustment 
both in nursing homes and amongst outpatients in some of the participating 
municipalities. Cognitive impairment amongst the elderly was ignored, or inappropriately 
diagnosed and treated by the family physician, the relatives and the patient him/her self. 
Nursing homes were only partly set up to take care of dementia patients.  
 
In light of these observations and in order to ensure a professional care and follow-up of 
AD participants in the Dementia Study in Northern Norway, the study administration had 
to provide competence building and assistance with the construction of a suitable 
dementia care in participating municipalities offering stimulation therapy. Health 
professionals from all municipalities were invited to 3 main courses dealing with general 
knowledge on dementia, diagnostic procedures in particular, but only 14 out of 70 GPs in 
the participating municipalities attended these courses. Further more, several teaching 
courses were provided at the municipality level.  
 
9.6 Diagnosis   
The same diagnostic tools and diagnostic criteria were used independently of recruitment 
method. Participants recruited in general practice were examined by the community 
health professionals whereas individuals recruited by screening were examined and 
diagnosed by physicians from the study visiting each of the participating municipalities. 
In both cases, experienced physicians conducted the clinical and neurological 
examination and referred the participants to cerebral CT. Cognitive performance was 
assessed by MMSE and the clock drawing test. In the present study depression was 
assessed through a semi-structured questionnaire and MADRS, and basic activities of 
daily living were assessed by BI. NPI identified psychiatric symptoms. Social living, 
medical history and current medical use were recorded. A comprehensive number of 
biochemical analyses were obtained and recorded from each AD participant. A family 
member or a caregiver completed or extended the medical history and described the 
impact of the disease on the caregiver’s health and social life and on patient´s ADL by 
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answering the Informant Questionnaire-Cognitive Decline in the Elderly (IQ-CODE)164.  
Blood pressure was recorded automatically by DINAMAP165 as mean arterial blood 
pressure (MAP) (Appendix 1). Dementia and Alzheimer’s disease were diagnosed by 
experienced physicians and geriatricians using the ICD-10 and DSM-IV-TR criteria. 
Diagnostic discrepancies were discussed with another geriatric colleague (Matti Viitanen) 
and solved by consensus using NINCDS-ADRDA criteria for probable AD. Those 
complying with the ICD-10, DSM-IV-TR and NINCDS-ADRDA criteria for probable 
AD and fulfilling the inclusion/exclusion criteria were asked to participate in the study.  
 
Inclusion criteria 
Patients could be included in the study if they had a recent diagnosis of probable AD, had 
not received any symptomatic treatment and were not suffering from any co-morbidity 
interfering with cognitive testing or ChEI treatment. MMSE sum score needed to be 10 
points or more, and age ≥ 65 but <100 years. Each participant signed informed consent 
before inclusion. As a majority of the AD participants were anticipated to have reduced 
consent competence, the informed consent was also co-signed by a spouse or next to kin 
to comply with Norwegian national guidelines and research legislations.    
 
Exclusion criteria 
Patients suffering from dementia other than AD, serious brain injuries, infectious diseases 
of the central nervous system or serious depression or psychosis were excluded. Patients 
with delirium or behavioural disturbances interfering with cognitive or clinical testing, 
reluctance to participate, or inability to understand the purpose of the study, or who had 




A panel consisting of psychiatric nurses, university lecturers and members of the 
Competence Centre of Dementia in Northern Norway (Kløveråsen) developed a program 
of stimulation therapy including physical activities and cognitive, sensory and social 
stimulation. A number of activities were recommended within each area (see Proposal for 
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intervention). This program was adjusted for each participant living in the interventional 
municipalities taking functional and educational level and occupational experiences into 
consideration. The stimulation was conducted for a minimum of 30 minutes 5 days a 
week for one year in close co-operation with the patient and his/her family or with trained 
health providers. A weekly log was used to record the daily stimulation activities. Health 
professionals conducted the stimulation in nursing homes, while community nurses or 
other caregivers guided by the nurses were responsible for the stimulation therapy of 
community dwellers living in their own homes. The stimulation program was monitored 
and adjusted during the period of intervention. Individuals living in municipalities 
offering standard care received ADL support, supervision and sustainable care, as 
required. 
 
Proposal for intervention  
Physical stimulation 
Walking with or without an assistant, preferably outdoors 
Other outdoor activities 




Wheel chair outdoors 
Sensory garden 
Cognitive and social stimulation 
Conversation or reminiscence groups 
Reading and remembering  
Playing card, chess or puzzles 
Problem solving or memory training 
Combined activities 
Training activities of daily living 
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Learning hand crafts in groups 
Visiting museums, farms and similar institutions 
 
Donepezil 
All AD participants were randomised double-blinded to donepezil or placebo in blocks of 
four to six by the Clinical Research Centre at the University Hospital in Northern 
Norway. (Flowchart 2) The randomisation codes were transferred to the pharmacy at the 
County Hospital of Nordland, Bodø.  Donepezil was prescribed to each AD participant 
by their GP according to national guidelines. Then, the pharmacy distributed donepezil or 
placebo to the AD participants in accordance with the prescription and the randomisation 
codes.    
 
Donepezil and placebo were delivered by Pfizer, who had no influence on the study, the 
analyses of the results or publications. 
 
9.8 Testing and follow-up 
The two test technicians were trained at the Department of Geriatrics at the University 
Hospital. To improve intra- and inter-rate reliability they observed and evaluated each 
other by testing a number of patients with MMSE, ADAS-Cog, the clock drawing test, 
NPI and MADRS. The same test technician followed each participant during the study 
period over one year. The same diagnostic procedures were used to test the self-reported 
cognitively healthy control group. 
 
During the one-year follow-up period MMSE, the clock drawing test and ADAS-Cog 
were performed at baseline and at 4, 8 and 12 months, whereas NPI, MADRS and BI 
were performed at baseline and at 12 months.  
 
At the end of the study, blood samples were collected from 152 of the AD participants 





10. Ethical considerations 
10.1 Consent competence 
AD individuals included in a clinical trial have varying degrees of reduced consent 
competence and reduced ability to understand oral or written information. In early 
disease stages, they usually are able to decide in a rational manner which choices will fit 
them best, participating in the study or not. At this stage a stand in should not be allowed 
to interfere with the patient’s decision. Later on, a spouse or a next of kin should be asked 
to take responsibility for the decision-making process on behalf of the patient. 
Monitoring patients with impaired cognitive functions who participate in an 
interventional clinical trial requires specially awareness. The monitor and caregiver must 
observe sign of adverse reactions and any expressed reluctance to participate or inability 
to understand the purpose of the study. Signs such as these require immediate exclusion 
from the study at any time during follow-up. Participants´ well-being must always be 
considered a main concern in any clinical trial, especially when it comes to participants 
with cognitive impairment 
 
10.2 Study design 
Ethical considerations of randomised placebo-controlled, double-blinded trials with new 
drugs for AD have been discussed since 1996166. It has been argued that Phase IV studies 
of ChEIs could be unethical according to the modest and statistically significant effect of 
the drugs on cognition167;168. However, the contradictory outcome of numerous RCTs on 
ChEI in addition to high drug costs and fear of adverse reaction underlay the decision to 
perform the present study.  
 
The medical history of chemicals with ChEI effects is scaring and should be considered 
carefully, especially as it comes to the development of new drugs aimed to treat 






The present study was approved in advance by national authorities including the Regional 
Committee for Medical Research Ethics in Northern Norway, the Privacy Ombudsman 
for Research, the Directory of Health and Social Welfare and the Norwegian Medicine 
Agency included registration of the study in the EudraCT database (no 2004-002613-37). 
Each AD participant gave written informed consent co-signed by a spouse, a close 
relative or a guardian. The national authorities listed above approved the consent formula 
and the study is also registered as an International Standard Randomized Controlled Trial 
within ClinicalTrials.gov (Identifier: NCT00443014). In October 2008 The Norwegian 
Medicine Agency conducted an inspection according to the principles of Good Clinical 
Practice (GCP) in a randomised clinical trial. All remarks from this assessment, including 
monitoring routines were closed and approved. The study was then given a signed 
approval by the Norwegian Medicine Agency as a RCT in accordance with the GCP 
criteria. All publications from this study comply with the CONSORT statements and the 
Uniform Requirements for Manuscripts Submitted to Biomedical Journals169;170.  
 
11. Data and statistics 
11.1 Data recording 
The demographic characteristics, medical history, clinical examination, cognitive tests 
and current medical use of AD participants and cognitively healthy controls were 
recorded at study entry. Cognitive tests were registered at four time points during one 
year for each AD participant. At the end of the study period the database was assessed, 
secured and locked by the Clinical Research Centre at The University Hospital in 
Northern Norway 
11.2 Statistics 
Statistical analysis was conducted using SPSS version 15.0 and 16.0(SPSS Inc. Chicago, 
IL, USA). Based on the calculation of power, a sample size of 64 in each group was 
necessary to detect a 2-point difference in mean MMSE sum score with 80% power, 
provided a standard deviation of 4 and a two-sided significance level of 5%. Differences 
in demographic characteristics between municipality groups and medicine groups and 
between recruitment methods as well as the comparison of co-morbidity and drug use 
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between AD participants and cognitively healthy controls were assessed by Chi-square 
and independent-samples t-tests. Analyses of co-variance (ANCOVA) and logistic 
regression were used for age and gender adjustment. Linear mixed models were used to 
assess time-trends in cognitive function over four time points and to assess differences in 
time-trends between groups of AD participants. Including an unstructured covariance 
matrix in the model controlled for possible dependences between repeated observations. 
In the municipality groups, time-trend differences in cognitive function were assessed 
between the stimulation group and control group, and differences in the medicine groups 
were assessed between the donepezil treatment group and the placebo group. Finally, the 
subgroup treated by stimulation therapy and donepezil was compared to the subgroup 
receiving usual care and placebo. Model assumptions were assessed by means of residual 
analyses. The statistical analyses were performed with intention-to-treat, per-protocol and 
subgroup analyses in order to estimate the homogeneity and consistency of the data. In 
the sensitivity analyses we included municipality as a random effect in the linear mixed 
models in order to control for possible clustering of data within the municipalities. 
 
12. Results  
12.1 Recruitment methods and baseline characteristics 
During the first year 27 AD individuals were included by GPs. After extending the 
recruitment method to comprise a population-based postal screening of cognitive function 
in individuals ≥ 65 years another 160 participants were included during the next year, 100 
by screening and 60 by GPs in clinical practice. In this way the study AD participants 
were included by two different recruitment methods (Flowchart 3).  
 
Participants recruited by screening were more frequently male (p< 0.001), younger (p = 
0.006), more independent and needed less community support (p< 0.001), as compared to 
those recruited by GPs. Also, they had a higher ADL function as assessed by the Barthel 
Index (p=0.011) and had a significantly higher MMSE sum score (p=0.001). No 
significant differences in neuropsychiatric symptoms (NPI) were found. Participants 
recruited by screening had a significantly higher MADRS score compared to participants 
recruited in clinical practice (Table 1).  
 40 
 
Further analyses revealed that each sample was equally distributed across the main study 
groups. No significant differences in age, gender, cognitive function, neuropsychiatric 
symptoms or need for ADL support were found between AD participants in the 
interventional municipalities compared to AD participants in the control municipalities 
(Table 2). 
 






























Invited to examination 
n=438 










Excluded, not AD 
n=116 





Table 1 Comparison of age, gender and MMSE score at baseline between recruitment 
methods 
  Recruitment method   
  Screening  Clinical practice  p-value 
Age ± SD  79.5 ± 7.5  82.3 ± 6.1  0.006 
MMSE ± SD   24.4 ± 2.9  21.3 ± 4.2  <0.001* 
Female n (%)  46 (46)  67 (77)  <0.001* 
Barthel Index ± SD  19.23 ± 2.07  17.96 ± 3.38  0.011* 
NPI ± SD  6.14 ± 8.49   8.18 ± 11.50  0.20* 
MADRS ± SD  3.19 ± 4.25  1.18 ± 2.70  0.001* 
In need of ADL support n (%)  28 (28)  57 (66)  <0.001* 
* Adjusted for age 
 
 
Table 2 Comparison of baseline characteristics between stimulation therapy and standard 
care. 
  AD participants receiving   
  Stimulation 
therapy 
 Standard care  p-value 
Age ± SD  81.2 ± 6.7  79.5 ± 7.3  0.10 
MMSE ± SD  22.6 ± 4.0  23.5 ± 3.7  0.14 
Female n (%)  59 (60)  54 (64)  0.25 
Barthel Index ± SD  18.64 ± 2.55  18.64 ± 3.20  0.995 
NPI ± SD  6.08 ± 9.59  8.49 ± 10.52  0.12 
MADRS ± SD  2.56 ± 4.29  2.12 ± 3.10  0.49 







12.2 A cross-sectional comparison of co-morbidities and current medication between 
participants with and without AD 
Data on past medical history, co-morbidities and current medication was recorded at 
study entry. AD participants were older (80.9 ± 7.0 vs 72.5 ± 5.5 p<0.001) and the female 
fraction was significant higher (60% vs 43% p<0.001) compared to controls. No 
significant age- or gender-adjusted differences in co-morbidities were found between AD 
participants stratified on disease stages. However, the total number of drugs was 
significantly higher in AD participants compared to controls despite no differences in co-
morbidities. When participants were stratified by ATC group a significant higher use of 
drugs with anticholinergic activity, anxiolytics/hypnotics and antidepressants was found 
in the AD group compared to the control group. Only four of the AD participants used 
antipsychotics. The number of antihypertensive drugs was significantly higher, nearly 
doubled, in AD participants compared to controls. 
 
One hundred and forty-two AD participants were living at home, 40 of them received 
ADL support from community nurses at least once a week. Forty-five AD participants 
lived in nursing homes (1 missing). Nursing home AD residents and the most disabled 
community dwellers used significantly more drugs than those living in their own homes 
without any regular ADL support. This included both the total number of drugs 
(p<0.001), drugs classified as inappropriate according to the STOPP criteria152 (p<0.001), 
drugs exhibiting the two highest levels of anticholinergic activity assessed by the 
Anticholinergic Risk Scale (ARS) (p=0.001)171, antidepressants (p<0.001) and 
anxiolytics/hypnotics (p<0.001) (Table 5). 
 
MAP (Formula 1) adjusted for age and gender was significantly lower in AD participants 
compared to controls. A family history of AD was significantly more common in AD 
participants compared to controls. Sixty-three per cent of the participants in the control 
group had completed ≥ 10 years of education compared to 17% in the AD group. 
However, after age and gender adjustment this was not significant (p=0.33).  
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Table 3 Comparison of drug use between AD participants with and without regular ADL 
support  
  Without 
community ADL 
support n=102 














MMSE ± SD 
  






Mean drug number± SD 
  
3.8 ± 2.5 
  






































12.3 Symptomatic treatment 
The follow-up period of AD individuals included in the study was one year. Cognition 
was tested four times at four-month intervals. Forty-one individuals dropped out during 
follow-up as a consequence of death (n=7), disease progression (n= 8), co-morbidities 
(n= 8) and withdrawal for unknown reason (n=18). One hundred forty-six completed the 
program (Flowchart 4). Forty-one AD participants (41.5%) in the stimulation therapy 
group completed a total of 200 or more sessions of stimulation therapy as assessed by 
approved logs during one-year follow-up whereas 53 AD participants (55.9%) in the 
donepezil group completed drug treatment for 42 weeks or more.  
 
No significant time-trend differences in cognitive test performance were found between 
AD participants receiving stimulation therapy and standard care as assessed by MMSE 
(primary outcome), the clock drawing test and ADAS-Cog (secondary outcome) during 
the one-year follow-up. Both AD participants allocated to stimulation therapy and AD 
participants allocated to standard care with or without donepezil retained cognitive 
function as assessed by the three tests. The results were consistent in the intention-to-treat 
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and per-protocol analyses (Chart 1). Subgroup analyses of participants with MMSE score 
≤25 (Chart 2 and Table 5), and MMSE score ≤ 21 at entry and stratified on recruitment 
methods (not in chart) were consistent with the intention-to-treat analyses.  
 
No significant time-trend differences in cognitive function between groups with 
donepezil and placebo with or without stimulation therapy were found (Chart 3). 
Participants receiving donepezil had significantly more adverse reactions (28%) than 
those receiving the placebo (10%) (odds ratio 3.80 95% CI 1.55 to 9.54 p=0.002). A 
subgroup analysis comparing the combined effect of stimulation therapy and donepezil 
versus standard care and placebo did not reveal any time-trend differences between the 
groups regarding cognitive achievements (Chart 4). On Chart 4 the expected decline in 
mean MMSE sum score is plotted. Stimulation therapy with placebo compared to 
donepezil treatment with standard care (representing a head to head comparison of 
stimulation therapy versus donepezil) did not demonstrate any time-trend differences in 
cognitive performance (Chart 5). Only small changes in ADL and neuropsychiatric 
functions were found after one-year follow-up (Table 4). Intention-to-treat, per-protocol 





Flowchart 4  


























MMSE sum score 
at test 1, n=146 
23.36 ± 4.44 
Dropouts n=7 
 
Sum dropouts  
Test 1 to test 4 n=34 
 
MMSE sum score at 
test 1, n=34 
22.16 ± 4.47 
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Chart 2 Mean MMSE sum score at each time point for all participants compared to 
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Time point (four-month intervals) 
 
All cases n=180 
Entry MMSE<26 n=114 
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Chart 4 The extreme limit comparison between donepezil combined with stimulation 
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Chart 5 Head to head comparison of stimulation therapy + placebo versus donepezil + 





Table 4 Neuropsychiatric symptoms and ADL function at entry and after one-year 
follow-up stratified by interventional groups. 
    Intervention 






 Donepezil  Placebo 
 Entry  18.64± 2.55  18.64 ± 3.20  18.87±2.12  18.41 ± 3.38 Barthel 
index 
 One year  18.41± 2.87  18.25 ± 3.59  18.50±2.45  18.17 ± 3.83 
           
 Entry  2.56 ± 4.29  2.12 ± 3.10  2.70 ± 4.22  2.04 ± 3.38  
MADRS  One year  2.63 ± 3.88  2.09 ± 3.61  2.71 ± 3.95  2.02 ± 3.52 
           
 Entry  6.08 ± 9.59  8.49 ± 10.52  7.49±11.14  6.70 ± 8.85  
NPI  One year  6.56 ± 9.57  9.61 ± 12.88  7.83±11.32  7.97 ± 11.27 
 
 









1 2 3 4 
Time points (four-month intervals) 
 
          Stimulation 
  Donepezil 
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Table 5. Mean cognitive test performances at follow-up time points in AD participants 
receiving stimulation therapy compared to standard care, and donepezil compared to 
placebo. Patients with entry MMSE ≤ 25 (n=114) 
  












8 months,  
n=105  
  











           
Stimulation  21.49  21.11  21.33  20.88  
Standard care  21.42  21.87  22.68  21.91  
 
0.044** 
           
Donepezil  21.85  21.92  22.37  21.42  





           
Stimulation  2.56  2.65  2.51  2.74  
Standard care  2.50  2.51  2.64  2.67  
 
0.478 
           
Donepezil  2.69  2.53  2.44  2.69  





           
Stimulation  21.16  21.08  19.59  19.77  
Standard care  20.33  19.13  19.09  19.38  
 
0.334 
           
Donepezil  20.85  19.78  18.96  19.16  
Placebo  20.79  20.84  19.82  20.09  
 
0.670 
*n varies due to dropouts during follow-up. ** Adjusted for gender p=0.37 Adjusted for age p=0.11 
†Adjusted for gender p=0.23. Adjusted for age p=0.85 
Adjusting for age or gender did not change other p-values in the analyses 
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13. Discussion  
13.1 Recruitment methods and selection bias. 
Baseline characteristics differed significantly between AD individuals recruited in 
clinical practice and by population-based screening. These findings underscore the 
impact of sampling methods aimed to select a representative study sample from the 
source population. Baseline characteristics of the AD participants should be similar to or 
not differ significantly from, the source population (internal validity). The present study 
was community-based with an unselected population of recently diagnosed AD 
participants recruited by GPs or by population-based screening (Flowchart 1). The 
clinical examinations were performed by experienced general practitioners supervised by 
geriatric specialists. The results confirm that different recruitment methods within the 
same population provide samples with significant differences in several baseline 
characteristics. Similar findings have been reported by Izal et al. who emphasise that 
recruitment method can specifically influence the outcomes of studies with elderly people 
and limit the generalization of their results9. Population-based recruitment conducted in 
the community without stringent inclusion criteria is supposed to come closest to a 
representative sample and should achieve the highest external validity99;172. 
 
Assessing internal validity172 in dementia studies is challenging. Dementia is still a 
syndrome based on clinical criteria without a golden standard. Few, if any, positive 
biomarkers are routinely in use and the current diagnostic tools rely upon questionnaires, 
tests and clinical examinations with insufficient accuracy and corresponding low 
sensitivity and specificity27;94. Sampling will therefore always be at risk of 
misclassification and selection bias. Women are at a higher risk of AD than men in some 
studies173;174. It is therefore important that gender distribution in the sample match that of 
the study population. According to 2008 Norwegian statistics, the female proportion of 
the population 67 - 79 years and 80 years and above are 53.6% and 65.0%, 
respectively175. In our study the gender distribution is similar to national statistics (Mean 
age 80.9 ± 7.0; 60.4% female).  
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According to the known incidence rate (2 – 4%)176 and prevalence (10%)71 of AD in the 
population 65 years and above, the number of eligible individuals with a recent diagnosis 
of AD in the participating municipalities was at least double what we were able to recruit. 
The screening program recruited younger and healthier individuals. Older eligible AD 
individuals with more advanced disease were possibly not accessible by a postal 
questionnaire as some of them were diagnosed earlier or lived in nursing homes. Studies 
on elderly may be biased by this healthy participant bias. GPs often hesitate to diagnose 
mild cognitive impairment or early-stage of dementia158. Mild to moderate cognitive 
impairment in the elderly, including early-stage AD, seems to be disregarded by both 
relatives and health professionals, even though this stage of cognitive impairment has the 
best response to intervention. Our findings are in accordance with others who reported 
that GPs tend to postpone a comprehensive examination of patients who complain of 
memory problems. When dementia is mild more than 90.9% of the cases are 
overlooked177. When dementia is severe the specificity is greater than 99%157;177;178.  
 
The questionnaire developed from the Cambridge Cognitive Examination and 
Strawbridge et al. along with the defined algorithm seemed to be highly valid in selecting 
individuals with cognitive impairment. Of 438 individuals selected by the algorithm to 
have probable cognitive impairment 229 underwent cognitive testing and clinical 
examination. Of these 113 were diagnosed with probable AD representing 2.9% of the 
responders (Flowchart 1) and more than one quarter of those selected by the algorithm. 
Seven hundred and ninety-one responders from the screening reported no cognitive 
impairment but still wanted to participate in the study. Five hundred individuals from this 
group were randomly allocated to the control group, and 200 received cognitive and 
clinical examination. All of them were confirmed to be cognitively healthy. In this way 
the present postal questionnaire combined with the algorithm was able to identify 
individuals with cognitive disabilities corresponding to early AD. 
 
In a large-scale community memory screening by Lawrence et al (2003) community 
dwellers were invited through the media to undergo cognitive assessment. Of those 
attending the screening program 1.5% had an undiagnosed AD. Considering the 
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prevalence of dementia, this was lower than expected, and the cost-effectiveness of the 
screening procedures could be questioned156.  However, in their study the invitation to the 
screening program came through media. No preliminary questionnaire specifically 
addressing cognitive complains followed the invitation and no algorithm was used. Crew 
et al. (2009) also used the media and flyers to recruit participants to be screened for 
cognitive impairment and neuropsychiatric symptoms. They found that 24% of the 
participants who completed the screening program received follow-up recommendation 
secondary to objectively identified age-inappropriate memory impairment. Crew et al. 
concluded that there appears to be a critical need for widespread use of screening 
programs to identify early age-inappropriate memory impairment155. 
 
According to the experiences of the present study, screening of cognitive impairment by 
mail with a preliminary questionnaire covering main cognitive domains followed by 
cognitive tests and clinical examination could be a useful tool to identify early stage AD 
in the community. However, screening such as this does not comply with a preclinical 
dementia stage or dementia risk factors179.  
 
13.2 Co-morbidities and current medication in participants with and without AD 
The cross-sectional analyses compared co-morbidities and current medication between 
AD participants and a cognitively healthy control group (paper 2). The results reveal an 
increased number of daily medications in AD individuals, especially anticholinergic and 
psychotropic drugs compared to the control group. Increasing drug consumption was 
associated with cognitive deterioration, the need for ADL support and institutionalisation. 
Psychotropic drugs exhibit an additional suppression of cognitive abilities in AD131;132. 
Adverse drug events increase from 10% with one drug to 75% in patients taking five 
drugs180. An increased number of drugs also increases the risk of potentially 
inappropriate medication181. In our study 48% of AD participants used five drugs or 
more. Nursing home AD residents used nearly seven drugs a day. Fifty-four per cents of 
AD participants living in nursing homes or in their own homes with regular ADL support 
from community nurses  used drugs defined inappropriate according to the STOPP 
criteria152. This finding could call for a more extensive adjustment of drug treatment 
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amongst AD individuals in primary health care or nursing homes. Interruption of 
inappropriate drugs may represent a therapeutic option to improve cognitive 
performance182, especially when it comes to simultaneous treatment with drugs exhibiting 
anticholinergic activities and ChEIs. 
 
AD is associated with cardiovascular risk factors and metabolic syndrome. However, the 
comparison of other co-morbidities between individuals with and without dementia has 
given ambiguous results82;183-185. In the present study, no age- or gender-adjusted 
differences in the number of co-morbidities between individuals with and without AD 
were found. This is in line with other studies184;185. However, AD individuals may suffer 
from more advanced illnesses186. In our study further analyses revealed a significantly 
lower mean arterial blood pressure and more antihypertensive drug use in AD 
participants compared to controls. This is in accordance with the findings of Guo et al187. 
The combination of reduced blood pressure and increased occurrence of vascular 
disorders, especially small-vessel diseases, could have an impact on cerebral perfusion 
and reinforce cognitive disabilities in individuals with a neurodegenerative disease108.  
When this is added to the heavy burden of inappropriate medical treatment both cognitive 
and ADL functions could be further suppressed. 
 
Low education has been identified as a risk factor in AD. Only 17% (33 of 187) of the 
AD participants had completed ≥ 10 years of education compared to 63% (126 of 200) of 
the control group. The mean age difference between the two study groups was 
approximately eight years, and this age difference could be related to differences in 
education attainment. At the beginning of World War II (1939/1940), the mean age of the 
AD participants in the present study was 12 years. Many inhabitants in Northern Norway 
lost several years of education as a consequence of the warfare. The mean age of the 
participants in the control group in 1939/1940 was 3 years, and they could easily make up 
for delayed school attendance after 1945. In our study, therefore, the difference in 




13.3 Symptomatic treatment  
The main result of this one year trial was that no differences in cognitive performance 
were detected between AD participants receiving stimulation therapy compared to AD 
participants receiving standard care. To our surprise both groups retained cognitive 
performance during the study period. The results were consistent for three different 
cognitive tests. This observation differs from other comparable studies23;125. The inherent 
trajectory in AD represents a decline in MMSE sum score of 2-3 points and an increase in 
ADAS-Cog score of 6 -12 points per year. The cognitive deterioration depend upon 
disease severity at baseline66;67;188.  The milder the baseline cognitive impairment, the 
slower the disease progression188. Stabilising cognitive performance is an important 
outcome in symptomatic treatment of AD38. Previous studies of symptomatic treatment 
with various designs have reported a postponement of disease progression for 
approximately one year in interventional groups37;125 and a variable cognitive decline in 
the control groups16;18;21;125;189. Equal effects, with retention of cognitive performance in 
both the interventional as well as the control groups, have to our knowledge not been 
reported. In concordance with results of previous studies, stimulation therapy and/or 
donepezil treatment in the present study was presumed to delay cognitive deterioration in 
the follow-up period. To our surprise, the control group receiving standard care with or 
without donepezil retained cognitive performance as well.  
 
Several events and mechanisms may explain the similar cognitive performances between 
participants receiving stimulation therapy and standard care. The equal effects on 
cognitive test performance in AD participants receiving stimulation therapy compared to 
standard care with and without donepezil with  preservation of cognitive abilities during 
one year could partly be explained by a placebo, expectancy or Hawthorne 
effect43;44;190;191. The present study was not designed to evaluate the placebo effect and 
the outcomes of the study have to be discussed with caution. However, participation in a 
trial like the present study, with frequent monitoring and follow-ups, may create 
expectancy192 and act as cognitive stimulation by itself. The test-technicians visited the 
municipalities regularly for three years. Their visits were obviously an important event 
booth for the AD participants and the caregivers. The question arises whether the placebo 
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effect of study participation could have provided high expectancy and cognitive 
stimulation in all subgroups leaving a possible stimulation and/or donepezil effect 
undetectable42;190;193. In a review of stimulation therapy in AD Olazaran et al. (2010) 
found that increased attention to the control groups reduced the differences in cognitive 
functions between interventional and control groups and could blur study results24. If so, 
this could have hampered other trials with symptomatic treatment of AD individuals and 
partly explain the contradictory results of many dementia studies. Neuropsychological 
mechanisms within the placebo effect could have seriously biased the outcomes.  
 
Benedetti et al found that the placebo effect depends upon preserved frontal lobe 
function. Decreasing executive functions were associated with a reduced placebo effect. 
In our study, frontal executive functions were not explicitly assessed, and retaining 
cognitive function during one-year follow-up was independent of disease stage measured 
by MMSE sum score at entry. The subgroup of AD participants with MMSE ≤ 21 at 
entry (n=59, mean MMSE sum score 18.4 ± 2.7) preserved cognitive performance during 
one-year follow-up as well.  
 
Previous studies of symptomatic treatment have reported a postponement of disease 
progression for approximately one year45;194. The stabilising effect on cognitive 
performance seems to occur irrespective of what symptomatic treatment was offered, 
whether stimulation therapy, symptomatic drug treatment, or stimulation therapy added to 
the symptomatic drug treatment (donepezil)125. The maintenance of the cognitive 
performances is an important treatment goal in AD.  Postponing functional worsening is 
favourable for both the patients and their caregivers38 and may delay institutionalisation 
for some AD patients18. 
 
Health professionals in both municipality groups attended the same dementia competence 
courses; whereas courses that aimed to qualify stimulation therapy providers were 
reserved for interventional municipality health professionals. A national campaign on AD 
was launched around the time of our study. These concomitant events could have diluted 
the municipality differences and influenced standard care in control municipalities. The 
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stimulation program in our study was developed by experienced dementia therapists, 
adjusted individually and provided by trained primary health nursing staff or 
caregivers/family members and was designed to be sustainable for months without 
extensive costs. So far, no standardised and validated stimulation therapy programmes 
are available195.  Growing evidence indicates that combining the stimulation benefits of 
educational, occupational and mental activities (cognitive reserves) with physical 
activities and a healthy life style are the most important modifiable risk factors in AD13;27. 
The stimulation program in the present study was in accordance with these 
recommendations.  
 
Except for adverse reactions, an effect of donepezil compared to placebo with or without 
stimulation therapy was not detectable. Both the donepezil and the placebo group 
retained cognitive function during one year follow-up.  
 
Interestingly the main result of the present study is in agreement with the casuistry 
described in the introduction.   
 
13.4 Strengths and weaknesses 
The present study was community-based with well defined but not too stringent 
inclusion/exclusion criteria. The sampling method was designed to recruit a 
representative sample of newly diagnosed AD participants from the source population. 
The population-based screening program provided in the present study is to, my 
knowledge, the only one conducted in Scandinavia. The participants remained in their 
own environment, and a significant number of participants completed the one-year 
follow-up. Few interventional studies with stimulation therapy have accomplished a one-
year follow-up. A study design such as ours, with a two-by-two factorial design, focusing 
on stimulation therapy and donepezil treatment and including a head-to-head comparison, 
has previously been advocated by the scientific community10 but has previously not been 
accomplished. The control group, consisting of self-reported and clinical confirmed 
cognitively healthy individuals, constitutes the only randomly selected control group in 
AD research in Norway. In April 2009, after an inspection according to the principles of 
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GCP in a randomised clinical trial, the study was given signed approval by the 
Norwegian Medicine Agency as an RCT conducted in accordance with the GCP criteria. 
 
The participating municipalities were not randomly selected but recruited according to a 
number of criteria, including the competence of the health providers, demographic 
characteristics of the population and geographic location. Choosing maximum distance 
and pursuing the least contact between interventional and control municipalities were 
done to minimise the risk of dilution. Such a non-randomised selection could be 
considered as a limitation of the study. However, the study population in the participating 
municipalities was ethnically and socially homogenous, and the baseline characteristics 
did not differ either between AD participants receiving stimulation therapy compared to 
standard care or between AD participants receiving donepezil or placebo. In addition, a 
sensitivity analysis in order to control for possible clustering of data within the 
municipalities did not change the results.  
 
 
The retention of cognitive function in the present study could have occurred because of 
early AD stage at entry with minimal cognitive decline during follow-up188. In a review 
by Sevigny et al. (2010) of a 12-month, multicentre, double-blinded RCT, the AD 
participants in the placebo group were dichotomised according to baseline MMSE sum 
score into mild disease (MMSE 21 – 26) and moderate to severe disease stage (MMSE 14 
- 20). The outcome measure was the percentage changes in ADAS-Cog score during the 
12-month follow-up. The total rate of cognitive decline in participants with mild AD 
according to ADAS-Cog was less than that of participants with moderate to severe AD196. 
Although AD participants in our study were examined, diagnosed and followed with a 
variety of tests, diagnosing mild AD remains a challenge. The mean MMSE sum score at 
baseline was 23.0 ± 3.9, representing the mild AD stage. According to Sevigny et al the 
cognitive decline in our study could therefore have been less than expected during 
follow-up. However, in the study analysed by Sevigny et al., all AD participants were 
treated with ChEI or memantine196, which could have had a different impact on cognitive 
decline in participants with mild AD compared to participants with moderate to severe 
 58 
AD during the 12-month follow-up. In our study, subgroup analyses of AD participants 
recruited by GPs (n=87), AD participants with MMSE sum score ≤ 25 at entry (n=121) 
and with MMSE sum score ≤ 21 at entry (n=55) were consistent with the intention to 
treat analysis.  
 
The subgroup analyses of the study cover a wide range of possible interactions between 
strata, independent variables and outcomes (Charts 2 and 5). Some of these two-by-two 
factorial strata are small and could be at risk of type II error. However, the results of all 




A population-based postal screening of cognitive function with a subsequent clinical 
examination is suitable to identify early-stage AD.  
 
AD individuals used significantly more medication than controls, and particularly the use 
of anticholinergic drugs is worrying. A careful evaluation and interruption of possible 
inappropriate drug use in AD individuals at any disease stage may represent a therapeutic 
option to improve cognitive performance. 
 
The two-by-two factorial design of The Dementia Study in Northern Norway provides an 
opportunity to compare the effects of two different interventional methods on cognitive 
performance in AD individuals. The negative effect of symptomatic treatment in AD with 
or without donepezil compared to controls, with retention of cognitive abilities in all 
groups during a one-year follow-up was a surprise and may have been a consequence of 
participants’ expectancy and the psychosocial context of the intervention. The possibility 
of postponing cognitive deterioration by at least one year in AD individuals with mild to 
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Appendix 1 Mean arterial pressure (MAP) 
               
MAP =  (Diastolic blood pressure x 2) + Systolic blood pressure     




The history of cholinesterase inhibitors (ChEI) 
The comprehensive neurological and toxicological effects of ChEIs have gradually been 
revealed in biological and medical literature over approximately 135 years, beginning 
with the discovery of physostigmine. The natural source of physostigmine was the calara 
bean from tropical West Africa which was brought to England in 1875. The effect was 
first described in the ophthalmology literature by Laqueur in 1876 and in 1936 the drug 
was synthesised by Percy Lavon Julian197. ChEIs play still a significant role in modern 
medicine as an important therapeutic option in ophthalmology and in the treatment of 
myasthenia gravis.  
 
The history of nerve gases began on 23 December, 1936, when Gerhard Schrader first 
prepared tabun which exhibits a strong non-competitive inhibition of acetyl 
cholinesterase. He continued to prepare new forms of tabun and observed the toxic effect 
of vaporised tabun on him self and his laboratory assistant. In 1939 a pilot factory for 
vaporised tabun production was set up at Munster-Lager, and the history of Nazi gas 
chambers was initiated (Paxman J et al: A higher Form of Killing: The Secret Story of 
Chemical and Biological Warfare, 1982).  
 
The vast majority of pesticides and herbicides have their main impact on 
neurotransmission. Some of the most neurotoxic chemicals, such as organophosphate and 
carbamate, are highly potent non-competitive ChEIs198 and may produce serious toxic 
reactions in mammals.  
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Most health professionals are well aware of the biological mechanisms behind ChEIs, 
their toxicity and their antidotes. During my own military service in the medical corps of 
the Norwegian Air Force I gave lectures about the disaster caused by chemical weapons 
including nerve gases, many of which have cholinesterase inhibition properties. Later on 
as a general practitioner, I taught farmers about the risks of pesticides, herbicides and 
insecticides for the farmer him/herself, the environment and the consumers.  
 
This brief review summarises the well-known physiological effect and toxicity of ChEIs. 
The possibility of adverse reactions to any chemicals with a ChEI effect must always be 
considered. Their conflicting and dramatic history in combination with their potential 
impact on vital neural and neuromuscular transmission in any creature makes the 
preparing of new ChEI derivatives for neurological purposes an ethical question, 
especially when it comes to “improving memory and learning in healthy subjects”199 and 
in studying and treating individuals with reduced consent competence.  
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